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Abstract
Epidermal growth factor receptor (EGFR) is commonly over-expressed in metastatic breast cancer yet metastatic breast
cancer is generally resistant to anti-EGFR therapies, and the mechanism for resistance to EGFR inhibitors in this setting is
not fully understood. Hormonally up-regulated neu-associated kinase (HUNK) kinase is up-regulated in aggressive breast
cancers and is thought to play a role in breast cancer metastasis. However, no studies have been conducted to examine a
relationship between EGFR and HUNK in breast cancer metastasis. We performed a kinase substrate screen and identified
that EGFR is phosphorylated by HUNK. Our studies show that HUNK phosphorylates EGFR at T654, enhancing receptor
stability and downstream signaling. We found that increased phosphorylation of T654 EGFR correlates with increased
epithelial to mesenchymal, migration and invasion, and metastasis. In addition, we found that HUNK expression correlates
with overall survival and distant metastasis free survival. This study shows that HUNK directly phosphorylates EGFR at
T654 to promote metastasis and is the first study to show that the phosphorylation of this site in EGFR regulates metastasis.
Introduction
The over-expression of epidermal growth factor receptor
(EGFR) is associated with poor clinical breast cancer out-
comes including early recurrence, increased risk of metas-
tasis, and decreased survival [1–5]. However, the efficacy of
anti-EGFR therapies (e.g., cetuximab and erlotinib) in
clinical trials was limited [2, 6, 7]. Cetuximab was tested in
a phase II trial of 31 patients with triple negative breast
cancer (TNBC), and only 2/31 patients responded to treat-
ment, despite the majority of tumors exhibiting over-
expression of EGFR [6]. Likewise, erlotinib was tested in a
phase II trial in 69 patients with metastatic breast cancer and
only 2/69 had a partial response, while 67/69 patients had
no response [2]. Consequently, additional studies are nee-
ded to understand the underlying mechanistic connection
between EGFR expression and metastatic progression.
Experimental studies support the observation that over-
expression of EGFR promotes metastatic phenotypes in
human breast cancer cells [1, 4, 5, 8–15]. In one study,
Appert-Collin et al. found that ligand-independent, con-
stitutively active forms of the receptor can promote meta-
static phenotypes of tumor cells [8]. In another study, Xue
et al. found that over-expression of EGFR in mammary
tumors resulted in increased lung metastases compared with
mammary tumors that do not over-express EGFR [5]. Other
studies showed that cells with elevated EGFR expression
had increased hyperinvasive capabilities compared with
cells with reduced EGFR [16]. Importantly, breast cancers
that over-express EGFR and exhibit increased metastatic
potential, are resistant to EGFR inhibitors [1, 17].
Hormonally Up-regulated Neu-associated Kinase
(HUNK) is a serine/threonine kinase that is a member of the
AMP-activated protein kinase (AMPK) family, and was
reported to be up-regulated in aggressive subsets of human
cancers including breast, ovarian, and colon cancers [18].
Experimental studies indicate a relationship between
HUNK and breast cancer progression [18–22]. Wertheim
et al. showed that Hunk wild-type (Hunk+/+) mice had
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significantly increased lung metastases compared with
Hunk-knockout (Hunk−/−) mice when bred into an MMTV-
myc background [18]. In addition, tumors derived from
Hunk−/− cells retrovirally transduced with a wild-type ver-
sion of HUNK (HUNK WT) had significantly increased
lung metastases compared with those transduced with either
a kinase dead version of HUNK (K91M) or a control vector
[18]. These data strongly suggest that HUNK promotes
breast cancer metastasis, and that this process is dependent
on HUNK kinase activity. However, another study provided
evidence that HUNK suppresses basal breast cancer
metastasis [23]. Quintela-Fandino et al. found that when
HUNK was exogenously introduced into basal breast cancer
cells, cell motility and tumor metastases were decreased
[23]. With these conflicting views on HUNK’s role in breast
cancer metastasis, further investigation is needed.
Currently, a mechanism for HUNK-mediated metastasis
has not been delineated. Furthermore, there are no known
substrates of HUNK. Identification of bona fide substrates
could give more insight into HUNK’s intracellular func-
tions, particularly in breast cancer. In this study, we show
that HUNK directly phosphorylates EGFR in its juxta-
membrane domain at threonine 654 (T654), resulting in
receptor stabilization and signaling. This effect corresponds
to an increase in epithelial to mesenchymal (EMT), cell
migration, and invasion in vitro. Furthermore, we show that
HUNK stabilizes EGFR expression in primary tumors,
which correlates with increased levels of phosphorylation of
EGFR at T654, resulting in an increase in lung metastasis
in vivo. These studies are novel because they are the first to
identify a substrate, EGFR, for HUNK and is the first study
to show that the phosphorylation of the T654 site in EGFR
regulates metastasis.
Results
HUNK phosphorylates EGFR at T654
We performed a HUNK substrate screen using an anno-
tated peptide microarray spotted with 720 peptides con-
taining known phosphorylation sites in human proteins. A
total of 293T cells were transfected with a Flag-tagged
HUNK wild-type (Flag-HUNK WT) followed by anti-
Flag immunoprecipitation and elution with Flag peptide.
The eluted kinase was applied to the peptide array with
ATP [γ-32P] to evaluate kinase activity toward the spotted
peptides. The results showed that HUNK phosphorylated
a peptide containing the sequence RHIVRKRTLRRLL
[24]. This peptide sequence maps to T654 and surround-
ing amino acids in the human EGFR protein (Fig. 1a). To
confirm that HUNK directly phosphorylates this site, we
performed an in vitro dot blot kinase assay using
recombinant HUNK isolated from Sf9 cells, and biotin-
tagged peptides containing the EGFR sequence
RHIVRKRTLRRLL (T-peptide), or the same sequence
but with an alanine in place of the threonine- RHIVRK-
RALRRLL (A-peptide) as substrates. The peptides were
incubated with ATP either in the absence or in the pre-
sence of HUNK. We also used staurosporine (STU) as a
pharmacological tool to inhibit HUNK kinase activity,
since prior studies show STU to bind and inhibit HUNK
[25, 26]. The kinase reactions were dotted onto nitro-
cellulose membrane and blotted with a phospho-specific
antibody for T654 EGFR (pT654). HUNK phosphorylated
the T-peptide, but not the A-peptide, and STU prevented
T-peptide phosphorylation (Fig. 1b, left panel). We
additionally blotted for biotin, using streptavidin-HRP, to
confirm the presence of substrate in each reaction (Fig. 1b,
right panel). These results indicate that HUNK directly
phosphorylated EGFR at T654, identifying EGFR as the
first HUNK substrate.
Next, we generated HUNK-deficient 293T cells using
Crispr/Cas9 with two individual sgRNAs to deplete HUNK
and a control cell line that had a sgRNA targeted to
AAVS1. Loss of HUNK was quantitated using quantitative
real-time PCR (Fig. 1c). We confirmed HUNK depletion
decreased pT654 EGFR (Fig. 1d). Since PKC was reported
to phosphorylate EGFR at T654 [24], we evaluated if PKC
activation or expression was affected by altering HUNK.
There was no change in the expression of PKC, phospho-
PKC (pPKC), or phosphorylation of PKC substrates (pPKC
substrates) (Fig. 1e). However, residual pT654 EGFR in
HUNK sgRNA targeted cells could be due to PKC activity,
which is present in HUNK depleted cells. To determine if
we could rescue the phosphorylation of EGFR at T654 in
the HUNK-deficient cells, we transfected Flag-HUNK WT
and kinase-inactive Flag-HUNK K91M into the HUNK_2B
293T cells (Fig. 1f) and found the addition of Flag-HUNK
WT into HUNK_2B 293T cells rescued the phosphorylation
of EGFR at T654, whereas expression of Flag-HUNK
K91M did not (Fig. 1g). Taken together, these data strongly
suggest that HUNK kinase activity directs the phosphor-
ylation of EGFR at T654.
HUNK regulates EGFR stability leading to
downstream signaling, increased EMT, cell
migration, and invasion
To investigate a role for HUNK regulation of EGFR in
breast cancer, we used shRNA to target HUNK in human
breast cancer cell lines that have high EGFR expression,
without altering PKC activity (Supplementary Figs. 1 and 2).
We engineered BT20 and MDA-MB-468 (human EGFR+
breast cancer cell lines) cells with control shRNA
(targeted to firefly luciferase) or shRNA targeted to HUNK
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(HUNK shRNA1 and shRNA2) (Fig. 2a and Supplementary
Fig. 2a). Downregulation of HUNK in BT20 and MDA-
MB-468 cells reduced the levels of pT654 EGFR (Fig. 2b
and Supplementary Fig. 2b).
Bao et al. found that the phosphorylation of EGFR at
T654 impedes EGFR ubiquitination and degradation,
resulting in sustained EGFR expression in the absence of
the receptor ligand, epidermal growth factor (EGF) [24].
We performed a cycloheximide (CX) chase analysis to
observe the role of HUNK in EGFR degradation. CX
inhibits translation by impairing ribosomal translocation,
and over time an unstable protein will decrease in expres-
sion whereas a stable protein will not [27]. Consistent with
Bao et al. observations, HUNK down-regulation rescued
EGFR degradation after CX treatment (Fig. 2c). In addition,
immunofluorescence of EGFR showed that the down-
regulation of HUNK reduced the amount of EGFR on the
cell surface (Fig. 2d).
EGFR dimerizes with itself and other EGFR family
members (e.g., HER2 and/or HER3), which causes an auto-
transphosphorylation event that activates the intracellular
kinase domains of the receptors, leading to phosphorylation
of tyrosine (Y) residues in the C-terminal tail of each
receptor [17]. Therefore, we evaluated EGFR, HER2, and
HER3 for levels of trans-autophosphorylation and saw
reduced phosphorylation of EGFR at Y1068 (Fig. 2e),
HER2 at Y1248 (Supplementary Fig. 1b), and HER3 at
Y1289 (Supplementary Fig. 1c) in BT20 cells. We saw the
same decrease in trans-autophosphorylation of EGFR at
Y1068 in MDA-MB-468 cells (Supplementary Fig. 2d).
Levels of pY1068 EGFR were also reduced in 293 T
HUNK_2B engineered cells when compared with the
Fig. 1 HUNK directly phosphorylates EGFR on threonine 654 (T654)
residue. a A substrate screen was performed using a peptide micro-
array (JPT). 293T cells were transfected with a Flag-tagged HUNK
wild type (Flag-HUNK WT), and Flag-HUNK WT was isolated using
a flag peptide elution method. The eluted kinase was then applied to
the peptide array to evaluate kinase activity toward spotted peptides,
with an EGFR peptide as a hit. b Dot blot kinase assay using an EGFR
peptide RHIVRKRTLRRLL (T-peptide) and RHIVRKRALRRLL (A-
peptide) as the substrate for recombinant HUNK. The peptide was
incubated with ATP with no kinase, with HUNK, and with HUNK and
staurosporine (STU). c Results from qPCR showing the crispr/cas9
depleted levels of HUNK in 293T control (AAVS1) and knock-out
(HUNK_2A and HUNK_2B). Western blot showing the expression
levels of (d) pT654 EGFR (HUNK_2A p < 0.01; HUNK_2B p < 0.05),
total EGFR (e) pPKC, pPKC substrates, and total PKC in 293T crispr/
cas9 cells. Graphs shows mean ± SEM (n= 3). 293T HUNK_2B cells
were transfected with vector, HUNK WT, and kinase dead HUNK
(HUNK K91M). Western blot showing the expression levels of (f)
HUNK, (g) pT654 EGFR (AAVS1 p < 0.05; HUNK_2B HUNK WT
p < 0.01; HUNK_2B K91M p < 0.05), and total EGFR in 293T
HUNK_2B transfected cells. All graphs show mean ± SEM (n= 3)
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control cells (Supplementary Fig. 3a). Moreover, the addi-
tion of Flag-HUNK WT into HUNK_2B 293T cells rescued
phosphorylation of EGFR at Y1068, whereas the addition
of Flag-HUNK K91M did not (Supplementary Fig. 3a),
further supporting that HUNK enhances EGFR activity. A
common downstream signaling pathway of activated EGFR
is the Ras-MAPK (ERK1/2) pathway [17, 28], which reg-
ulates EMT, tumor invasion, and metastasis [7]. To deter-
mine if HUNK regulates the activation of ERK1/2, we
evaluated control shRNA and HUNK shRNA expressing
BT20 and MDA-MB-468 cells for levels of ERK1/2
phosphorylation (pERK1/2). Concomitant with the down-
regulation of pY1068 on EGFR, the down-regulation of
HUNK reduced pERK1/2 (Fig. 2e and Supplementary Fig.
2d). We also evaluated the expression of pERK1/2 in 293 T
control and HUNK_2B engineered cells transfected with
Flag-HUNKWT and Flag-HUNK K91M and found that the
addition of Flag-HUNK WT into HUNK_2B 293T cells
increased the expression of pERK1/2, whereas the addition
of Flag-HUNK K91M did not (Supplementary Fig. 3b). In
addition to ERK1/2, studies have shown that focal adhesion
kinase (FAK) can associate with activated EGFR signaling
complexes to aid in cell migration [29, 30]. Therefore, we
evaluated control shRNA and HUNK shRNA expressing
BT20 and MDA-MB-468 cells for FAK activation and saw
that the downregulation of HUNK reduced pFAK (Fig. 2e
and Supplementary Fig. 2d).
Recently, activated EGFR signaling has been shown to
promote EMT, which generates cells with stem-like prop-
erties [31] and drives cells to dissociate from the primary
tumor and migrate/invade into surrounding tissues [7, 32].
Studies have shown that activation of EGFR and subsequent
activation of ERK1/2 results in upregulation of Snail [33].
Furthermore, studies have shown that Snail and E-cadherin
Fig. 2 HUNK regulates pT654 EGFR and EGFR-directed metastatic
signaling in BT20 cells. a qPCR results showing the level of HUNK
knock-down in BT20 cells with control, HUNK shRNA1 (p < 0.001),
and HUNK shRNA2 (p < 0.01). b Western blot showing the expres-
sion levels of pT654 EGFR and total EGFR in control, HUNK
shRNA1 (p < 0.05), and HUNK shRNA2 (p < 0.05) BT20 cells. c
Control, HUNK shRNA1, and HUNK shRNA2 BT20 cells were
treated with cycloheximide (CX) over the course of 8 h, and western
blot showing the expression levels of EGFR (CX-4 h HUNK shRNA1
p < 0.05; CX-4 h HUNK shRNA2 p < 0.001; CX-8 h HUNK shRNA1
p < 0.01; CX-8 h HUNK shRNA2 p < 0.001). d Immunofluorescence
showing cell surface EGFR expression in control, HUNK shRNA1 (p
< 0.05), and HUNK shRNA2 (p < 0.05) BT20 cells. Western blot
showing the expression levels of (e) pY1068 EGFR (HUNK shRNA1
p < 0.05; HUNK shRNA2 p < 0.05), total EGFR, pERK1/2 (HUNK
shRNA1 p < 0.05; HUNK shRNA2 p < 0.05), total ERK1/2, pFAK
(HUNK shRNA1 p < 0.05; HUNK shRNA2 p < 0.01), and total FAK.
All graphs show mean ± SEM (n= 3)
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expression are inversely correlated in breast cancer [34, 35].
Therefore, we looked at expression of Snail and E-Cadherin
in BT20 and MDA-MB-468 cells. The down-regulation of
HUNK decreased Snail expression (Fig. 3a and Supple-
mentary Fig. 2e), whereas E-Cadherin expression was
increased (Fig. 3a and Supplementary Fig. 2e). We next
performed mammosphere formation assays with our control
shRNA and HUNK shRNA expressing BT20 cells and
found the downregulation of HUNK decreased primary
mammosphere formation as well as mammosphere renewal
capacity (Fig. 3b). MDA-MB-468 cells were not tested for
mammosphere formation as these cells were previously
shown to be deficient for this property [36], and we were
also unable to get spheres to form.
We next performed transwell migration assays to mea-
sure cell migration between control versus HUNK shRNA
cells. The down-regulation of HUNK in BT20 and MDA-
MB-468 cells reduced transwell cell migration (Fig. 3c and
Fig. 3 HUNK regulates EGFR-directed metastatic phenotypes in BT20
cells. a Western blot showing the expression levels of Snail (HUNK
shRNA1 p < 0.05; HUNK shRNA2 p < 0.05), and E-Cadherin (HUNK
shRNA1 p < 0.05; HUNK shRNA2 p < 0.05) in control, HUNK
shRNA1, and HUNK shRNA2 BT20 cells. b Mammosphere forma-
tion assay of 500 control, HUNK shRNA1, and HUNK shRNA2 BT20
cells at original/day 7 (HUNK shRNA1 p < 0.01; HUNK shRNA2 p <
0.001) and renewal/day 14 (HUNK shRNA1 p < 0.05; HUNK
shRNA2 p < 0.001). c Transwell migration (HUNK shRNA1 p < 0.05;
HUNK shRNA2 p < 0.01) and (d) invasion (HUNK shRNA1 p < 0.05;
HUNK shRNA2 p < 0.05) assays showing cell migration and invasion
of 250,000 control, HUNK shRNA1, and HUNK shRNA2 BT20 cells
after 24 h. All graphs show mean ± SEM (n= 3 for a–c, n= 4 for d)
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Supplementary Fig. 2f). In addition to cell migration, we
evaluated cell invasion using transwell chambers with
matrigel-coated membranes and found that the down-
regulation of HUNK decreased cell invasion in comparison
to control cells (Fig. 3d and Supplementary Fig. 2g). In
order to evaluate the effects of HUNK kinase activity and
EGFR T654 phosphorylation on cell migration, we also
performed transwell migration assays with the 293 T
AAVS1 and HUNK_2B engineered cells. We found that
reduction of HUNK expression reduced cell migration, and
ectopic expression of Flag-HUNK WT into HUNK_2B
293T cells increased cell migration, whereas the addition of
Flag-HUNK K91M did not (Supplementary Fig. 3c).
To further investigate the roles of T654 in downstream
EGFR signaling, we obtained a phospho-deficient mutant of
EGFR at the T654 site (T654A EGFR) [5, 24]. We trans-
fected EGFR wild-type (EGFR WT), and T654A EGFR
into 293T cells and western blot analysis confirmed there
was little to no phosphorylation of T654 on EGFR in cells
transfected with T654A EGFR versus EGFR WT (Fig. 4a).
Cells transfected with T654A EGFR displayed a reduction
in pY1068 EGFR, pERK1/2, pFAK, and Snail (Fig. 4a)
compared with cells transfected with EGFR WT. These
results further confirm that the phosphorylation of T654
promotes EGFR activation and downstream signaling. We
also performed transwell migration assays on 293T cells
transfected with either EGFR WT or T654A EGFR, and
Fig. 4 The phosphorylation of T654 on EGFR promotes breast cancer
lung metastases. a Western blot showing the expression levels of
pT654 EGFR (p < 0.01), pY1068 EGFR (p < 0.05), total EGFR,
pERK1/2 (p < 0.01), total ERK1/2, pFAK (p < 0.05), total FAK, Snail
(p= 0.05) in 293T cells transfected with EGFR WT or T654A EGFR.
b Transwell migration assay (p < 0.01) showing cell migration of
150,000 293T cells transfected with EGFR WT or T654A EGFR after
24 h. cWestern blot showing the expression levels of pT654 EGFR (p
< 0.05), pY1068 EGFR (p < 0.05), total EGFR, pERK1/2 (p < 0.05),
total ERK1/2, pFAK (p < 0.01), total FAK, and Snail (p < 0.01) in
67NR and 4T1 cells. d Western blot showing expression levels of
pT654 EGFR and total EGFR from 67NR and 4T1 tumors. e qPCR
results showing the level of Hunk knock-down in 4T1 cells with
control shRNA_4, Hunk shRNA_4A (p < 0.001), and Hunk
shRNA_4B (p < 0.01). f Western blot showing expression levels of
pT654 EGFR and total EGFR from 4T1 control, Hunk shRNA_4A,
and Hunk shRNA-4B tumors. Images and graphs showing (g) gross
metastasis (identified white asterisks) in the lungs of mice bearing
control, Hunk shRNA_4A (p= 0.08), and Hunk shRNA_4B 4T1 (p <
0.05) tumors and (h) micrometastases (identified black arrows) in the
lungs of mice bearing control, Hunk shRNA_4A (p < 0.01), and Hunk
shRNA_4B 4T1 (p < 0.01) tumors. Box plots show mean and spread
of data set (n= 6–12). All other graphs show mean ± SEM (n= 3 for
a, c–e; n= 4 for b)
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cells transfected with T654A EGFR displayed a significant
reduction in cell migration compared with cells transfected
with EGFR WT (Fig. 4b). Altogether, our findings are the
first to demonstrate that HUNK-directed phosphorylation of
EGFR at T654 contributes to multiple metastatic
phenotypes.
Phosphorylation of T654 EGFR by HUNK promotes
mammary tumor lung metastasis
To determine if HUNK regulates breast cancer metastasis
in vivo, we used the 4T1 cell line, which was originally
isolated as subpopulation 410.4 derived from a sponta-
neously arising mammary tumor in BALB/cfC3H mice, and
is defined as an animal model for stage IV human breast
cancer with spontaneous metastatic capability [37–40]. As
our non-metastatic control, we chose to use the tumor
subpopulation line 67, which was isolated from a single
spontaneously arising mammary tumor from a BALB/
cfC3H mouse [37], and was transfected with bacterial pSV2
plasmid to obtain geneticin-resistant 67NR cell line that is
tumorigenic but will not spontaneously metastasize [41].
To first determine the significance of phosphorylation of
EGFR at T654 on metastasis, we compared levels of pT654
EGFR between the two cell lines and saw a significant
increase in pT654 EGFR levels in the 4T1 metastatic
compared with the 67NR nonmetastatic breast cancer cells
(Fig. 4c). In addition, there was a significant increase in
pY1068 EGFR, pERK1/2, pFAK, and Snail in the 4T1 cells
compared with the 67NR cells (Fig. 4c). We also compared
pT654 EGFR levels in tumors derived from the 67NR and
4T1 tumor cells. There was less pT654 EGFR in the 67NR
tumor lysates, whereas the 4T1 tumors showed higher
expression of pT654 EGFR (Fig. 4d). These results suggest
that the phosphorylation of EGFR at T654 correlates with
and metastatic potential in vitro and in vivo.
Next, we engineered the 4T1 metastatic mammary tumor
cell line to have normal (control shRNA_4) and reduced
(Hunk shRNA_4A and Hunk shRNA_4B) Hunk expression
(Fig. 4e). HUNK down-regulation reduced pY1068 EGFR,
pERK1/2, and Snail (Supplementary Fig. 4a), similar to our
findings in the human BT20 and MDA-MB-468 cells. In
addition, downregulation of HUNK reduced mammosphere
formation of 4T1 cells (Supplementary Fig. 4b), as well as
cell migration and invasion (Supplementary Fig. 4c, d).
These results confirmed that HUNK promotes metastatic
phenotypes in the 4T1 cell line.
Next, control and Hunk shRNA 4T1 cells were ortho-
topically introduced into the abdominal mammary gland of
Balb/c mice and monitored for in vivo tumor growth and
lung metastasis. There was no significant difference in
tumor growth between experimental groups (Supplemen-
tary Fig. 5a), consistent with previous findings [18].
Western blot analyses showed that tumors derived from
Hunk knockdown 4T1 cells had reduced overall expression
of pT654 EGFR as well as total EGFR expression com-
pared with control cells (Fig. 4f). We observed a decrease
in gross visible metastases in lungs from animals injected
with 4T1 Hunk shRNA expressing cells compared with
those derived from control cells (Fig. 4g). In addition,
lungs derived from mice injected with 4T1 Hunk shRNA
expressing cells had reduced numbers of lung micro-
metastases when analyzed by H&E staining (Fig. 4h).
These results suggest that HUNK promotes breast cancer
lung metastasis.
Pharmacological inhibition of HUNK reduces
mammary tumor lung metastasis
Prior studies show STU to bind and inhibit HUNK [25, 26].
Therefore, we performed a dose-response analysis of STU in
4T1 cells to test the effect on phosphorylation of EGFR at
T654. Increasing STU concentrations decreased the expres-
sion of pT654 EGFR (Fig. 5a), while causing no change in
the activity of PKC (Fig. 5b). When cells were pre-treated
with either DMSO or STU and the remaining live cell plated
for transwell migration analysis, drug treatment decreased cell
migration when compared with DMSO treated cells (Fig. 5c).
We also treated BT20 cells with STU and performed western
blot analysis to determine the effect of STU treatment on
pT654 EGFR and PKC activity. STU treatment significantly
decreased pT654 EGFR levels compared with cells treated
with DMSO (Supplementary Fig. 6a), and STU treatment did
not change the activity of PKC in the BT20 cells (Supple-
mentary Fig. 6b). Importantly, STU treatment significantly
decreased BT20 cell migration when compared with DMSO,
consistent with our findings in 4T1 cells (Supplementary
Fig. 6c).
To investigate the effects of pharmacological inhibition
of HUNK on breast cancer metastasis in vivo, we orthoto-
pically implanted 4T1 cells into the abdominal mammary
gland of BALB/c mice. Once the tumors reached an average
size of ~65 mm3, mice were randomly divided into two
treatment groups of either placebo or 3 mg/kg STU. Once
the tumors reached a maximum size of ~4000 mm3, the
tumors and lungs were harvested. STU treatment sig-
nificantly reduced the expression of pT654 EGFR in tumors
compared with placebo (Fig. 5d). There was also no sig-
nificant difference in tumor volume between the groups
(Supplementary Fig. 5b). However, STU significantly
decreased the number of gross visible lung metastases
(Fig. 5e) and lung micrometastases per animal (Fig. 5f).
Taken all together, our results suggest that pharmacological
inhibition of HUNK impairs the phosphorylation of EGFR
at T654 in primary mammary tumors and consequently,
impairs metastasis.
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pT654 increases with breast cancer stage and HUNK
expression in human breast cancers correlates with
overall survival and distant metastasis free survival
To further confirm our overall observations, we performed
an analysis using a TMA containing samples from triple-
negative breast cancer patients with stage I–III breast can-
cers, to analyze the levels of pT654 EGFR throughout
different stages of disease. We observed a significant
increase in pT654 EGFR expression in Stage 3 versus Stage
1/2 tumors (Fig. 6a and Supplementary Fig. 7). In addition,
we performed analyses using the Kaplan–Meier Plotter
database tool (kmplot.com) to assess whether HUNK
expression correlated with overall (OS) or distant metastasis
free survival (DMFS) [42]. The Affimetrix gene probe for
HUNK (1555935_s_at) was used for analysis with all
clinical data available selected (e.g., all subtypes). For OS, a
total of n= 314 patients were scored as “low” HUNK and n
= 312 were scored as “high” HUNK. The online tool
automatically removed redundant samples, excluded any
biased arrays, and did not include any proportional hazard
assumptions. The probe expression range was 2–1074 with
a cutoff value of 84 used for analysis. These parameters
showed that high HUNK expression corresponded with
decreased OS (Fig. 6b). For DMFS, a total of n= 334
patients were scored as “low” HUNK and n= 330 were
scored as “high” HUNK. In this analysis, the probe
expression range was 2–1074 with a cutoff value of 91 used
for analysis. These parameters showed that high HUNK
expression corresponded with decreased DMFS (Fig. 6c).
Altogether, we have shown that HUNK promotes metastasis
by phosphorylating EGFR, resulting in downstream sig-
naling events that drive metastatic behavior of breast cancer
cells (Fig. 7).
Discussion
The majority of breast cancer-related deaths are not due to
primary tumor growth, but rather the metastatic spread of
the primary tumor to distant organs [43]. Since metastasis is
the cause of most cancer-related deaths, it is important to
identify the sequence of events that leads to the develop-
ment of cancer cell invasion and metastasis. EGFR over-
expression has been linked to metastatic phenotypes and
metastatic breast cancers are considered resistant to EGFR
inhibitors, which have not been clinically effective at
reducing metastasis or overall survival in breast cancer
Fig. 5 The pharmacological inhibition of HUNK impairs breast cancer
lung metastasis. Western blot analyses showing the STU dose-
response effects on expression of (a) pT654 EGFR, total EGFR,
(b) pPKC-alpha, PKC-alpha, pPKC-delta, pPKC-lamda/zeta, pPKC-
mu, pPKC-theta, pPKC substrates, and total PKC in STU dose-
response in 4T1 parental cells. c Transwell migration assay (p < 0.05)
showing cell migration of 50,000 cells after 24 h of 4T1 parental cells
pre-treated with either DMSO or 25 nM STU. Graphs shows mean ±
SEM (n= 4). d Western blot showing the expression levels of pT654
EGFR and total EGFR in 4T1 parental tumors treated with placebo or
3 mg/kg STU. Images showing (e) gross metastasis (p < 0.01) (iden-
tified black arrows) and (f) micrometastases (p < 0.05) (identified black
arrows) on the lungs of mice treated with placebo or 3 mg/kg STU.
Box plots show mean and spread of data set (n= 6–12)
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patients [1, 17]. This could be due to increased metastatic
potential of these tumors, but nonetheless, emphasizes the
need for new therapeutic targets in patients that fail anti-
EGFR therapies.
We found that through the phosphorylation of EGFR at
T654, HUNK significantly increased metastatic phenotypes
in breast cancer cells and mammary tumor metastasis
in vivo. Our studies are consistent with other studies that
demonstrate that the phosphorylation of EGFR at T654
maintains receptor stability in vitro, and EGFR over-
expression enhances breast cancer metastasis in vivo
[5, 24]. However, we are the first to show that phosphor-
ylation of EGFR at T654 corresponds to increased breast
cancer metastasis in vivo. In addition, we are the first to
show that pT654 EGFR expression increases with higher
human breast cancer stages (i.e., stage 3 » stage 1 and 2
breast cancers).
In addition, we have previously shown that STU
inhibited HUNK’s kinase activity, and can therefore be
used as an experimental tool to study HUNK activity
[26]. We found that STU treatment of animals orthoto-
pically transplanted with 4T1 cells reduced the phos-
phorylation of EGFR at T654 in primary mammary
tumors, which corresponded to a decrease in EGFR
expression and lung metastases. Thus, this is the first
study to show that the pharmacological inhibition of
HUNK reduces metastatic potential of breast cancer cells.
Furthermore, we are the first to identify a kinase specific
molecular mechanism for HUNK in driving metastasis
and delineate the signaling pathway that HUNK acts
through during this process. Our data clearly shows that
pharmacological inhibition of HUNK supports this
mechanism, which also has not been previously deter-
mined. While a prior publication demonstrates that
pharmacological targeting of HUNK can impede tumor
growth, those studies were performed in a resistant
HER2-positive (HER2+) breast cancer cell model and
not a metastatic breast cancer model [26]. This point is
important to note because the fundamental mechanism for
HUNK in HER2+ breast cancer is different from
metastasis since tumor growth is not affected by HUNK
targeting in metastatic models [18]. Whether this is due to
differential signaling regulation or a cell type difference
is yet to be determined.
Our data shows that PKC is not inhibited in 4T1 cells
at the doses used to impair phosphorylation of EGFR at
T654. Although prior studies demonstrate a low nM
concentration range for inhibition of PKC isoforms by
STU, this has not been evaluated in 4T1 cells prior to the
present study. Therefore, it is possible that STU has a cell
type or context specific affinity for HUNK in cells where
HUNK is the predominant kinase acting on EGFR at
T654. In addition, HUNK activity toward EGFR is likely
supported by different cell physiological conditions that
PKC activity toward EGFR, which requires calcium-
dependent signaling [24]. Our findings support this
notion as none of the six isoforms of PKC that we eval-
uated for activation after STU treatment showed a
decrease in phosphorylation. Consequently, it is reason-
able to speculate that STU did not inhibit PKC under the
Fig. 6 HUNK expression predicts overall survival and distant metas-
tasis free survival in human breast cancers. a A total of 64 Stage 1/2
tissues and 32 Stage 3 tissues were analyzed for pT654 expression and
graphs shows mean ± SEM. The Affimetrix gene probe for HUNK
(1555935_s_at) was used for analysis with all clinical data available
the selected (e.g., all subtypes). For OS, a total of n= 314 patients
were scored as “low” HUNK and n= 312 were scored as “high”
HUNK. The online tool automatically removed redundant samples,
excluded any biased arrays, and did not included any proportional
hazard assumptions. The probe expression range was classified by the
online tool as 2–1074 with a cutoff value of 84 used for analysis. b For
DMFS, a total of n= 334 patients were scored as “low” HUNK and n
= 330 were scored as “high” HUNK. In this analysis, the probe
expression range was classified by the online tool as 2–1074 with a
cutoff value of 91 used for analysis
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experimental conditions used to evaluate pT654 EGFR in
4T1 cells.
In summary, we show that the phosphorylation of EGFR
at T654 corresponds to increased metastatic potential
in vitro and in vivo, and correlates with higher stage human
breast cancers. Most importantly, this is the first study to
highlight EGFR T654 phosphorylation as a mechanism for
breast cancer metastasis, and the first to show that phar-
macological inhibition of HUNK impairs breast cancer
metastasis. It is exciting to speculate that the phosphoryla-
tion of this residue could coincide with de novo EGFR
inhibitor resistance in metastatic breast cancer, in particular
triple-negative breast cancer that typically express high
levels of EGFR. Looking forward, these findings have the
potential to translate into a positive impact for the overall
survival of patients with metastatic breast cancers that over-
express EGFR.
Materials and methods
Radioactive kinase assay
For identification of HUNK substrates by peptide array,
293T cells were transfected with Flag-HUNK and the cells
were lysed in buffer containing 50 mM Tris-HCl, pH 7.5,
150 mM sodium chloride, 1 mM EDTA, 1% Triton X-100
and HALT protease and phosphatase inhibitor cocktail
(Thermo Scientific). Flag- HUNK was immunoprecipitated
with anti-Flag M2 magnetic beads (Sigma, M8823) and
eluted with 0.25 µg/ml Flag peptide (Sigma). Eluted Flag-
HUNK WT was allowed to autophosphorylate in kinase
buffer (20 mM HEPES, pH7.3, 2 mM MgCl2, 0.1 mg/ml
BSA, 1 mM dithiothreitol, 100 µM ATP) for 20 min at
30 °C before addition of 50 µCi ATP-[ɣ-32P] (Perkin
Elmer) and incubation for 1 hr at 30 °C with an annotated
peptide array slide (JPT Peptide Technologies) containing
human peptides with known phosphorylation sites, in tri-
plicate. The peptide array was washed five times with 0.1 M
phosphoric acid, dried and the radioactive image developed
on a Storm 840 Phosphor Imager (Amersham). Phos-
phorylated peptide identification was verified by JPT Pep-
tide Technologies.
Dot blot kinase assay
Biotin-tagged peptides were purchased from Biomatik.
HUNK underwent a 30-min preincubation step at 30 °C
with 5 μM STU and ATP before peptides were added.
Kinase reactions were incubated at 30 °C for 15 min, and
part of the reaction was dotted on 0.2 μm nitrocellulose
membrane (Biorad) using bio-dot microfiltration apparatus
(Biorad), probed with a phospho-specific antibody to T654
on EGFR (pT654 EGFR), and developed on the Protein
Simple FluorChem-R imaging system using HyGLo che-
miluminescent detection reagent (Thomas Scientific). The
biotin tag to assess total peptide was probed for with
streptavidin-HRP.
Immunofluorescence
Cells were plated and allowed to incubate on coverslips
overnight. The following day the cells were fixed to cov-
erslips using 4% Paraformaldehyde (PFA) Solution
(Thermo Scientific). A permeablization step was not per-
formed to preserve cell surface EGFR. After fixation,
Fig. 7 HUNK promotes breast
cancer metastasis through the
phosphorylation of EGFR at
T654. HUNK directly
phosphorylates EGFR at T654
causing impaired EGFR
degradation and sustained
EGFR-directed metastatic
signaling in breast cancer
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primary antibody EGFR (528) (Santa Cruz) antibody was
used, followed by secondary antibody Alexa Fluor 594 anti-
mouse IgG (Life Technologies). After antibody incubations,
the coverslips were mounted to slides using ProLong Dia-
mond Antifade Mountant with Dapi (Invitrogen). The slides
were allowed to dry overnight (in the dark) at room tem-
perature, and images were acquired with a Leica confocal
microscope.
Mammosphere formation assay
Mammosphere media was composed of a 1:1 mix of
DMEM (Corning) and Hams F-12 (Corning) media sup-
plemented with 2% B-27 supplement (Gibco), 20 ng/ml
EGF (Sigma), 20 ng/mL FGF-basic (Invitrogen), and
heparin (StemCell Technologies). Equal number of cells
were plated in ultralow attachment plates at low density.
After 7 days, mammosphere counts were recorded and
images were acquired with Labomed iVu 5100 light
microscope and PixelPro software. For secondary renewal
analysis, mammospheres were collected and incubated with
0.05% trypsin for 5 min to produce single cell suspension.
The cells were plated at the original density, and allowed to
grow an additional 7 days, imaged and quantified.
Transwell migration and invasion assays
Equal number of cells were plated in the top of the transwell
inserts (VWR or Corning) or Matrigel coated invasion
chamber inserts (Corning) in serum-free media. Normal
growth media was placed in the bottom of the transwell
apparatus. After 24 h, the transwell membranes were fixed
in 4% PFA, and then stained with crystal violet. Images
were acquired with Labomed iVu 5100 light microscope
and PixelPro software, and the number of migrated cells
was quantified using ImageJ software.
Animal care
Animal care and experiments were approved and executed
under the guidelines of the Medical University of South
Carolina IACUC. All animals were housed and cared for in
the AAALAC accredited Animal Research Center at the
Medical University of South Carolina, and routinely mon-
itored by lab and veterinary staff. Animals were euthanized
by isoflurane overdose in accordance with the Guide for the
Care and Use of Laboratory Animals. Protocols were in
place for early and humane endpoints in the event that an
experimental animal displayed signs of illness. To deter-
mine if and when the animals should be euthanized, tumor
measurements and health monitoring was performed reg-
ularly by lab and veterinary staff.
In vivo metastasis analysis
Mice were acquired from Jackson Labs. Six to eight week-
old, female, BALB/c mice underwent abdominal mammary
gland injection with 50,000 4T1 control shRNA_4 cells (n
= 6), 4T1 Hunk shRNA_4A cells (n= 12),or 4T1 Hunk
shRNA_4B cells (n= 12). For STU treatment, (n= 18)
6–8 week-old, female, BALB/c mice were injected with
100,000 4T1 parental cells. Once the tumors reached a
volume of 65 mm3, placebo or 3 mg/kg STU oral gavage
treatments were started (n= 6 per treatment group, 2× per
week). Drugs were resuspended in 0.5% hydro-
xypropylmethylcellulose, 0.1% Tween-20, and 50% DMSO
(placebo).
Tissue microarray (TMA) analysis
The TMA (BR1922) was acquired from US Biomax, Inc.
The microarray contained 96 cases of invasive ductal car-
cinoma, with 78 cases in midstage, and 18 cases in
advanced stage. Duplicate cores were present for each case,
and divided into two identical 96 core arrays. One of the
cores was stained with pT654 EGFR (GeneTex), and the
other core was stained with EGFR (528) antibody (Santa
Cruz). After staining, the pT654 EGFR and EGFR cores
were view on a Hamamatsu Nanzoomer, and images of
each core were captured with Aperio ImageScope software.
The expression levels of pT654 EGFR and EGFR were
analyzed on ImageJ software.
Statistical analysis
Group measurements for cell-based assays were compared
using a two-tailed Student’s t-distribution. Error bars
represent the standard error of the mean. Data are repre-
sentative of at least three independent experiments with at
least three individual replicates or more per experiment.
IC50 was calculated using GraphPad Prism software.
Micrometastases were analyzed using negative-binomial
regression, and groups were compared by estimating the
relative fold changes between groups using the model’s
estimated coefficients. Gross metastases were summarized
descriptively, and proportions of presence or absence of
metastases compared between groups using Fisher’s exact
test. All tests were two-sided α= 0.05. Survival analysis
was performed using the tools provided on kmplot.com.
The high and low expression groups are determined using a
median split for the patients included in the particular
analysis, i.e., OS and DFMS. Differences in survival dis-
tributions between the two expression groups are compared
using the log-rank test, and hazard ratios are reported with
their 95% confidence intervals.
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